GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Debt-to-Equity

SRDX (Surmodics) Debt-to-Equity : 0.28 (As of Sep. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Surmodics Debt-to-Equity?

Surmodics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.0 Mil. Surmodics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $32.2 Mil. Surmodics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $118.9 Mil. Surmodics's debt to equity for the quarter that ended in Sep. 2024 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Surmodics's Debt-to-Equity or its related term are showing as below:

SRDX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.14   Max: 0.28
Current: 0.28

During the past 13 years, the highest Debt-to-Equity Ratio of Surmodics was 0.28. The lowest was 0.03. And the median was 0.14.

SRDX's Debt-to-Equity is ranked worse than
54.4% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 0.22 vs SRDX: 0.28

Surmodics Debt-to-Equity Historical Data

The historical data trend for Surmodics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Debt-to-Equity Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.10 0.14 0.28 0.28

Surmodics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 0.27 0.28 0.28

Competitive Comparison of Surmodics's Debt-to-Equity

For the Medical Devices subindustry, Surmodics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Surmodics's Debt-to-Equity falls into.



Surmodics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Surmodics's Debt to Equity Ratio for the fiscal year that ended in Sep. 2024 is calculated as

Surmodics's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surmodics  (NAS:SRDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Surmodics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Surmodics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics Business Description

Traded in Other Exchanges
N/A
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
Executives
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344